The Ras/mitogen-activated protein kinase (MAPK) pathway is a central signalling cascade that transmits extracellular growth and differentiation cues to nuclear effectors. Germline mutations in ...
Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S. commercial ...
We recently determined that concurrent inhibition of autophagy, using the lysosomal inhibitor chloroquine (CQ), and of ERK, using a small molecule ERK inhibitor (ERKi), synergistically suppressed the ...
Promising early clinical data about the drugs ERAS-007 and ERAS-601 has led to a trial studying the combination of the two drugs in treating patients with RAS/MAPK pathway-driven cancers. The first ...
Relapses in a common form of leukemia may be preventable following new research that has identified how the cancer develops resistance to first line treatments. The research published in iScience by ...
A drug that targets a molecular pathway involved in many types of cancer extends survival rate of pancreatic cancer patients by more than a year on average, according to new results from a clinical ...
Expect to Begin Rolling Submission of New Drug Application (NDA) for Accelerated Approval to FDA for Avutometinib and Defactinib Regimen in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in H1 2024 ...
Concurrent Inhibition of The RAS Pathway and Autophagy As a Treatment Approach for Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is characterized clinically by poor survival and mechanistically by KRAS- and autophagy-dependent growth. We and others previously demonstrated that inhibition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results